Ipratropium/Salbutamol Comparator Versus Originator for Chronic Obstructive Pulmonary Disease Exacerbations : USA Observational Cohort Study Using the Clinformatics™ Health Claims Database
| dc.contributor.author | Thomas, Vicky | |
| dc.contributor.author | Gefen, Eran | |
| dc.contributor.author | Gopalan, Gokul | |
| dc.contributor.author | Mares, Rafael | |
| dc.contributor.author | McDonald, Rosie | |
| dc.contributor.author | Ming, Simon Wan Yau | |
| dc.contributor.author | Price, David B. | |
| dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en |
| dc.contributor.institution | University of Aberdeen.Institute of Applied Health Sciences | en |
| dc.date.accessioned | 2017-07-03T09:00:24Z | |
| dc.date.available | 2017-07-03T09:00:24Z | |
| dc.date.issued | 2017-06 | |
| dc.description | Acknowledgements The authors wish to thank Priyanka Raju Konduru of Observational and Pragmatic Research Institute Pte Ltd (OPRI) for assistance with data extraction. This study was sponsored and funded by Teva Branded Pharmaceutical Products, R&D, Inc. Lynanne McGuire, PhD, of MedVal Scientific Information Services, LLC (Princeton, NJ, USA) provided medical writing and editorial assistance. This manuscript was prepared according to the International Society for Medical Publication Professionals’ ‘Good Publication Practice for Communicating Company-Sponsored Medical Research: the GPP3 Guidelines.’ Funding to support medical writing assistance was provided to MedVal by Teva Branded Pharmaceutical Products R&D, Inc., Frazer, PA, USA. Teva provided a full review of the article and provided funding of the journal’s article processing charges. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. | en |
| dc.description.status | Peer reviewed | en |
| dc.format.extent | 19 | |
| dc.format.extent | 860461 | |
| dc.identifier | 102160357 | |
| dc.identifier | 340f4ed5-9ba5-491d-b150-dd6786aba47d | |
| dc.identifier | 85103411299 | |
| dc.identifier.citation | Thomas, V, Gefen, E, Gopalan, G, Mares, R, McDonald, R, Ming, S W Y & Price, D B 2017, 'Ipratropium/Salbutamol Comparator Versus Originator for Chronic Obstructive Pulmonary Disease Exacerbations : USA Observational Cohort Study Using the Clinformatics™ Health Claims Database', Pulmonary Therapy, vol. 3, no. 1, pp. 187-205. https://doi.org/10.1007/s41030-017-0041-7 | en |
| dc.identifier.doi | 10.1007/s41030-017-0041-7 | |
| dc.identifier.iss | 1 | en |
| dc.identifier.issn | 2364-1746 | |
| dc.identifier.uri | http://hdl.handle.net/2164/8911 | |
| dc.identifier.vol | 3 | en |
| dc.language.iso | eng | |
| dc.relation.ispartof | Pulmonary Therapy | en |
| dc.subject | Albuterol | en |
| dc.subject | Drugs, generic/therapeutic use | en |
| dc.subject | DuoNeb® | en |
| dc.subject | Pharmacogenomics | en |
| dc.subject | Real-world | en |
| dc.subject | Steri-Neb™ | en |
| dc.subject | R Medicine (General) | en |
| dc.subject.lcc | R1 | en |
| dc.title | Ipratropium/Salbutamol Comparator Versus Originator for Chronic Obstructive Pulmonary Disease Exacerbations : USA Observational Cohort Study Using the Clinformatics™ Health Claims Database | en |
| dc.type | Journal article | en |